Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant taletrectinib versus placebo in resected ROS1-positive non-small cell lung cancer
2025-521971-29-00Phase 3Authorised
- Sponsor
- Nuvation Bio
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Taletrectinib with Placebo comparator (2 arms). Primary endpoint: Disease-free survival by investigator assessment. Planned start Jun 2026; status: authorised.
02
Drugs
taletrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521971-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521971-29-00.